INTELLIGENT BIO SOLUTIONS INC (INBS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$1.76+0.57%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · INBS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -75.1% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 56.0% |
Growth built into the price is above our model estimate.
The price assumes 131.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 29 industry peers
INBS — private placement
Dated 2026-09-02
Entry into a Material Definitive Agreement. On August 31, 2026, Intelligent Bio Solutions Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single institutional investor for the sale by the Company of (i) 2,036,659 shares (the “Shares”) of the Company’s common stock (or Series M Pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”)), par value $0.01 per share (the “Common Stock”), (ii) Series N-1 warrants to purchase up to an aggrega…
Why it matters: The filing is a key step toward planned U.S. market entry. A delay or FDA question could push that plan back.
Watch forThe company confirms it filed the 510(k) in September 2026. It reports FDA acceptance or review progress, with no major request for data.
Also watch forThe company says it missed its September 2026 filing target. Or the FDA asked for more clinical data.
Why it matters: The deal adds shares and warrants. More dilution could weigh on each existing share, even as it brings in capital.
Worry ifA filing or company update shows that 2,036,659 shares were issued. It also shows warrants were exercised or added to shares outstanding.
Less concerning ifThe company reports no more share issues or warrant exercises. Shares outstanding stay near the pre-deal level.
Why it matters: Margin growth came from lower costs and more cartridge sales. A sharp drop would weaken the case for better unit economics.
Watch forFiscal Q1 gross margin is at least 48.6%, near the fiscal 2026 level of 48.63%.
Also watch forFiscal Q1 gross margin falls below 46%, well under the fiscal 2026 level and Q3's 50.5%.
Why it matters: Cartridges drove repeat sales, while the reader base grew. Slower growth would test whether customer use keeps rising.
Watch forOn November 11, fiscal Q1 revenue grows year over year, and cartridge sales also rise year over year.
Also watch forFiscal Q1 revenue or cartridge sales fall year over year, or cartridge growth drops below the 35% full-year rate.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$273 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $981 loss on $10,000 · 9.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,196 loss on $10,000 · 92.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.